HC Wainwright & Co. Reiterates Buy on PMV Pharma, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on PMV Pharma (NASDAQ:PMVP) and maintained a price target of $5, as stated by analyst Robert Burns.
August 20, 2024 | 10:50 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on PMV Pharma and maintained a $5 price target, indicating confidence in the company's potential.
The reiteration of a Buy rating and maintenance of a $5 price target by a reputable analyst can positively influence investor sentiment and potentially lead to a short-term increase in PMVP's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100